Press Releases

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and Chief Executive Officer, Joseph C. Papa, will present at the...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer, Judy L. Brown, will present at...

Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 31, 2012. (Logo:...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on June 19,...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its third quarter fiscal 2012 on Tuesday, May 8, 2012...

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Chairman, President and CEO Joseph C. Papa will present at the Barlcays Capital Global...

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated market launch and made its first shipments of minoxidil 5% foam to its retail and...

Perrigo Company (Nasdaq: PRGO;TASE) today announced its Chairman & CEO Joseph Papa will present at the RBC Capital Markets' Healthcare Conference on...

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown will present at the Leerink Swann 2012 Global Healthcare Conference on...

Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its second quarter and six months ended December 31, 2011. Perrigo's Chairman and CEO...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on March 20,...

Perrigo Company (Nasdaq: PRGO;TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2012 on Tuesday,...

Perrigo Company (Nasdaq: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application...

Perrigo Company (NASDAQ: PRGO; TASE) announced today that the United States District Court for the Western District of Michigan has granted summary...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 30th Annual J.P. Morgan Healthcare...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its...

Perrigo Company (NASDAQ: PRGO; TASE) today announced it received Food and Drug Administration (FDA) clearance to market and distribute infant formula...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has entered into Cooperation and License agreements with Brilite Nutritionals (Shanghai)...

Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine...

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl...

Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its first quarter ended September 24, 2011. Perrigo's Chairman and CEO Joseph...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on December...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has entered into a supply agreement with Founder Pharma Co., Ltd., a wholly owned...

Perrigo Company (Nasdaq: PRGO; TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2012 on Thursday, October 27,...

Perrigo Company (Nasdaq: PRGO;TASE) announced that it received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown and Senior Management will meet with analysts on Wednesday, October 5,...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa and Senior Management will meet with analysts on...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its...

Perrigo Company (Nasdaq: PRGO; TASE) today announced it expects to issue $350 million of notes in its fiscal second quarter pursuant to its existing...

Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 25, 2011. Perrigo's Chairman and CEO...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its fourth quarter fiscal 2011 on Tuesday, August 16 ,...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has closed the acquisition of Paddock...

The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize the regulatory approvals necessary to complete the...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Goldman Sachs 32nd Annual Global...

Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle all Hatch-Waxman litigation relating to fluticasone lotion brought by...

Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 26, 2011. Perrigo's Chairman and CEO Joseph C. Papa...